H.C. Wainwright lowered the firm’s price target on Valneva to $20 from $23 and keeps a Buy rating on the shares following the investor day. The firm cites more conservative initial sales estimates for Ixchiq and VLA15 for the target cut. The analyst believes Valneva’s lyme disease vaccine is a potential blockbuster.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN: